Travere Therapeutics, Inc. TVTX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s stock issuance proceeds?
- Travere Therapeutics, Inc. (TVTX) reported stock issuance proceeds of $4.73M in Q1 2026.
- How has Travere Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?
- Travere Therapeutics, Inc.'s stock issuance proceeds increased by 11.5% year-over-year, from $4.24M to $4.73M.
- What is the long-term trend for Travere Therapeutics, Inc.'s stock issuance proceeds?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $189.28M to $0.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.